Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HuR siRNA
- Development stage
- Preclinical
- Lead developer
- Lankenau Institute for Medical Research
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
HuR siRNA is an experimental RNA interference (RNAi) therapeutic modality designed to silence the expression of the HuR gene (Human Antigen R, also known as ELAVL1). HuR is an RNA-binding protein that is frequently overexpressed in various malignancies, including pancreatic, lung, and breast cancers. It plays a central role in post-transcriptional regulation by binding to and stabilizing mRNAs that encode oncoproteins involved in cell proliferation, epithelial-to-mesenchymal transition (EMT), metastasis, and drug resistance. By utilizing small interfering RNA (siRNA) to trigger the degradation of HuR mRNA, this approach aims to downregulate these oncogenic factors and inhibit tumor progression. Various delivery systems are under investigation to improve the stability and tumor-specific uptake of the siRNA, such as the siHuR-3DNA nanocarrier, which utilizes a transferrin-conjugated DNA nanoparticle for targeted delivery.
- Other names
- siHuRELAVL1 siRNAELAVL-1 siRNAELAVL 1 siRNAHu-antigen R siRNA
02
Targets
ELAVL1 (Human Antigen R)
Beyond the preview
Go deeper on HuR siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HuR siRNA.